Whole Exome Sequencing (WES), which covers over 22,000 human genes, 180,000 exons and 60 million genomic loci, is a simple, economic and efficient solution for clinical applications. It largely improves variation calling accuracy thanks to its high coverage in targeted genome region. With a self-developed intelligent reporting system consists of WES data process and interpretation for hereditary diseases, Aegicare offers our clients precise, fast, economic and credible services.
Cancer is one of the most complex genetic diseases. With continuous progress in genetic testing, as well as growing researches on tumor related genes, such as driving genes and drug resistance genes, a lot more genes have been revealed to be closely related to the effectiveness of anti-tumor drugs.
Relying on advanced NGS sequencing platform and world-leading algorithms of genomic data processing, Aegicare provides cancer patients and physicians the most precise decision support, including detection of lung cancer, gastric cancer, colorectal cancer, breast cancer and other types of solid tumor.
Clinical Decision Support System (CDSS) is the main practice of the artificial intelligence theory in healthcare. It connects clinical observations to clinical knowledge, influences clinical decision-making and improves clinical results.
Aegicare’s CDSS provides clinicians with accurate, credible and up-to-date knowledge of treatment to achieve making optimal diagnoses, optimizing treatment options and improving patient outcomes. It also helps physicians to access to a life-time learning, improve diagnosis and treatment quality, and helps patients getting better healthcare and reduced medical cost.